The Innovative Medicines Initiative’s Big Data for Better Outcomes Programme (BD4BO) organizes a symposium “In data we trust: towards outcomes-based healthcare in Europe“. The symposium will take place on 11 October 2018 in Brussels, Belgium.
In Europe, there is a considerable amount of patient and healthcare data available with much more on the horizon. These data sources are often siloed and represent only a partial record of a patient’s experience in the healthcare system. When such different data sources are linked together, they offer a richer, more complete source of clinical patient data and have an enormous potential to make healthcare delivery more efficient, personalised and
to improve health outcomes. However, is there enough trust from all stakeholders to realise the full potential of Big Data? How can Big Data make healthcare systems sustainable? What steps can be taken to ensure that the use of Big Data will meet the expectations patients and citizens have of their healthcare system and improve health outcomes? Intense discussion to find the answers are to be expected.
HARMONY Partner, Prof Natacha Bolaños, Regional Coordinator, Lymphoma Coalition Europe is presenting. In addition she will take part in the round-table discussion (14.00-15.00 hrs.) on how trust in the use of Big Data can be strengthened to transform healthcare systems.
Link to the BD4BO symposium program >
The HARMONY Alliance is funded by the Innovative Medicines Initiative’s (IMI). IMI Big Data for Better Outcomes Programme (BD4BO) was launched in 2016, with a planned time-frame of about 10 years. Its overall objective is to maximize the potential of Big Data in European healthcare, and to promote innovative methods for harmonizing, accessing, and analysing data. Read more >>
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
